What is Inqovi and How Does it Compare to Vidaza?
Inqovi (decitabine and cedazuridine) is an oral formulation of decitabine, a hypomethylating agent, combined with cedazuridine, an inhibitor of the enzyme cytidine deaminase [1]. This combination is designed to increase the oral bioavailability of decitabine [1]. Vidaza (azacitidine) is another hypomethylating agent used in the treatment of myelodysplastic syndromes (MDS) [2]. Both drugs work by altering DNA and RNA in cancer cells, which can lead to the death of cancer cells and the development of normal blood cells [1, 2].
How Does Inqovi Work Differently Than Vidaza?
The primary difference lies in their administration and formulation. Inqovi is an oral medication, taken by mouth, while Vidaza is typically administered via subcutaneous injection or intravenous infusion [1, 2]. The combination of decitabine with cedazuridine in Inqovi aims to improve the absorption of decitabine when taken orally, reducing the need for injections [1]. Both drugs target DNA methylation, but they are distinct chemical entities with different pharmacokinetic profiles.
What Are the Approved Uses for Inqovi and Vidaza?
Both Inqovi and Vidaza are approved for the treatment of myelodysplastic syndromes (MDS) [1, 2]. Specifically, Inqovi is indicated for adult patients with MDS, including those with previously treated or untreated MDS and chronic myelomonocytic leukemia (CMML) [1]. Vidaza is approved for patients with MDS who have one or more of the following features: 5q- chromosomal abnormality in the absence of 22q11.2 deletion syndrome, or IPSS cytogenetic risk groups of intermediate-2 or high [2].
What Clinical Data Supports Inqovi's Effectiveness?
The efficacy of Inqovi was established in a Phase 3 clinical trial, ASTX727-001 (DECIDER), which demonstrated that oral decitabine and cedazuridine was non-inferior to intravenous decitabine in terms of overall survival for patients with MDS and CMML [1].
When Does Patent Protection Expire for These Drugs?
Patent information for specific drugs can be complex and may involve multiple patents covering the drug substance, formulation, and method of use. Detailed patent expiry information for Inqovi and Vidaza can be found on DrugPatentWatch.com [3].
What Are the Potential Side Effects of Inqovi and Vidaza?
Common side effects associated with Inqovi include neutropenia, thrombocytopenia, anemia, diarrhea, nausea, constipation, and fatigue [1]. Vidaza's common side effects include neutropenia, thrombocytopenia, anemia, leukopenia, nausea, vomiting, diarrhea, and fatigue [2]. It is important to note that both medications can cause serious side effects, and patients should discuss any concerns with their healthcare provider.
Are There Other Treatment Options for MDS Besides Inqovi and Vidaza?
Yes, other treatment options for MDS exist, depending on the subtype, severity, and patient's overall health. These may include other hypomethylating agents, growth factors, immunosuppressive therapy, chemotherapy, and stem cell transplantation [4].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/inqovi
[2] https://www.drugpatentwatch.com/drug/vidaza
[3] https://www.drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndromes/diagnosis-treatment/drc-20351344